• HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US
  • HOME
  • ABOUT US
  • PRODUCTS
    • LIST OF COPP
    • LIST OF PRODUCTS
  • CAREER
  • BLOG
  • CONTACT US

FDA approves PHESGO to treat HER2-positive breast cancer

July 22, 2020
-
News
-
Posted by seoaccount medivisual
PHESGO-HER2-positive-breast-cancer-admac

On 29 June 2020, a novel fixed-dose combination of trastuzumab, pertuzumab, and hyaluronidase–zzxf (PHESGO, Genentech, Inc.) for subcutaneous injection to treat HERS-2 (human epidermal growth factor receptor 2) positive breast cancer was approved by US FDA (United States Food and Drug Administration).

It can be used in combination with chemotherapy as

  • neoadjuvant treatment of patients suffering from HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either node-positive or greater than 2 cm in diameter) as part of a complete treatment regimen for the early stage of breast cancer
  • adjuvant treatment of patients with HER2-positive early breast cancer at greater risk of recurrence

It can also be utilized in combination with docetaxel for the management of patients with HER2-positive metastatic breast cancer who have not been treated with prior anti-HER2 therapy or chemotherapy.

A randomized, open-label, multicentre clinical trial (FeDeriCa) was conducted to explore the efficacy of PHESGO. Overall, 500 operable or metastatic HER2-positive breast cancer patients were incorporated in the study. Subjects were randomized to either i.v (intravenous) administration of pertuzumab and trastuzumab during the neoadjuvant and adjuvant chemotherapy or neoadjuvant therapy with PHESGO.

Estimation of non-inferiority of cycle 7 pertuzumab serum trough concentration assessing PHESGO versus i.v pertuzumab was the primary outcome. Estimation of cycle 7 trastuzumab serum trough concentration, safety, and pCR (pathological complete response) were the secondary outcome measures.

In comparison with pertuzumab and trastuzumab, PHESGO illustrated non-inferior pertuzumab and trastuzumab serum trough concentrations. The values of the pCR rate in the PHESGO group and the i.v pertuzumab and trastuzumab group are shown in the following table:

PHESGO groupi.v pertuzumab and trastuzumab GROUPpCR rate59.70%59.50%

The safety profile of PHESGO was found to be similar to i.v pertuzumab and trastuzumab, except for elevated administration-related reactions. In >30% of patients receiving PHESGO, the most frequent adverse effects noted were nausea, diarrhea, asthenia, alopecia, and anemia.There are two phases of PHESGO dosing. PHESGO’s initial dose is subcutaneously given for approximately 8 minutes and contains trastuzumab 600 mg, pertuzumab 1,200 mg, and hyaluronidase 30,000 units. The second dose is given subcutaneously every 3 weeks for approximately 5 minutes and contains trastuzumab 600 mg, pertuzumab 600 mg, and hyaluronidase 20,000 units.All serious adverse effects suspected to be linked with the use of any device or medicine should be reported by healthcare professionals to FDA’s MedWatch Reporting System.

Source

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-combination-pertuzumab-trastuzumab-and-hyaluronidase-zzxf-her2-positive-breast-cancer

Original title of the article FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer

← PREVIOUS POST
Avelumab as maintenance therapy to treat bladder cancer
NEXT POST →
Importance of Okra for Cancer Patients

Related News

Other posts that you should not miss.
soy-and-breast-cancer-admac

Role of soy in preventing Breast Cancer

September 30, 2020
-
News

Breast cancer, the most common cancer among women, affects 2.1 million women each year, and is responsible for greatest number of cancer-related deaths among women. Some types of …

Read More →
Posted by seoaccount medivisual
4 MIN READ
ripretinib-receives-FDA-approval-admac-oncology

Ripretinib receives FDA approval to treat the Advanced Gastrointestinal Stromal Tumours

December 11, 2020
-
News

The U.S. Food and Drug Administration approves Ripretinib tablets as the first new drug as a fourth-line therapy for treating the advanced gastrointestinal stromal tumour (GIST). GIST is …

Read More →
Posted by admin
2 MIN READ
exercise-for-cancer-prevention-admac

Exercise: A vital cancer prevention strategy

September 29, 2020
-
News

Worldwide, more than 10 million individuals are diagnosed with cancer. According to International Agency for Research on Cancer (IARC), 25% of cancer cases are due to obesity, overweight, …

Read More →
Posted by seoaccount medivisual
4 MIN READ
Please speak to us:
  • Phone:+91 172 2565161 , +91 172 2565162
  • Email : admac@admacinternational.com
Admac House
SCO 84, Sector 5,
Panchkula (Haryana)
134112 INDIA.
Our aim

At Admac we aim at providing innovative World-Standard medicines for all, at affordable prices. Admac is fully committed towards WHO standards; quality & growth, latest technology & R & D with sheer hard work and dedicated team work.

All Rights Reserved. 2016
Powered  by: Admac Oncology
FDA approves PHESGO to treat HER2-positive breast cancer | Admac